Literature DB >> 3325431

Activity of fosmidomycin in an in vitro model of the treatment of bacterial cystitis.

Y Kanimoto1, D Greenwood.   

Abstract

The response to fosmidomycin of four strains of Escherichia coli was studied in an in vitro model of the treatment of bacterial cystitis. Three susceptible strains of E. coli responded well to relatively low concentrations of fosmidomycin: doses achieving peak concentrations of 50 or 250 mg/l suppressed bacterial growth for 13 h or more; however, when the surviving bacteria were challenged with a second dose, a reduced response was observed. When a fully resistant strain was exposed to fosmidomycin, bacterial growth was also suppressed for 13 h or more, even when the peak concentration achieved was below the conventionally determined minimum inhibitory concentration. Resistant variants which emerged after exposure to fosmidomycin were also resistant to fosfomycin in the absence of the potentiating agent, glucose-6-phosphate. In the presence of glucose-6-phosphate, complete (or partial) susceptibility to fosmidomycin and fosfomycin was retained by three of the four strains. These results suggest that fosmidomycin and fosfomycin are transported into E. coli by a similar mechanism, and that deletion of the hexose phosphate transport system does not occur following exposure to fosmidomycin in the absence of glucose-6-phosphate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3325431     DOI: 10.1007/bf01647239

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  12 in total

1.  Factors influencing the activity of the trometamol salt of fosfomycin.

Authors:  D Greenwood; A Jones; A Eley
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

Review 2.  An in vitro model of the urinary bladder.

Authors:  D Greenwood; F O'Grady
Journal:  J Antimicrob Chemother       Date:  1978-03       Impact factor: 5.790

3.  An in-vitro model simulating the hydrokinetic aspects of the treatment of bacterial cystitis.

Authors:  D Greenwood
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

4.  FR-31564, a new phosphonic acid antibiotic: bacterial resistance and membrane permeability.

Authors:  H Kojo; Y Shigi; M Nishida
Journal:  J Antibiot (Tokyo)       Date:  1980-01       Impact factor: 2.649

5.  The trometamol salt of fosfomycin: microbiological evaluation.

Authors:  D Greenwood; S Coyle; J Andrew
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

6.  In vitro and in vivo antibacterial activity of FR-31564, a phosphonic acid antimicrobial agent.

Authors:  H C Neu; T Kamimura
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

7.  Pharmacokinetic profile of fosfomycin trometamol (Monuril).

Authors:  G Segre; E Bianchi; A Cataldi; G Zannini
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

8.  Studies on new phosphonic acid antibiotics. III. Isolation and characterization of FR-31564, FR-32863 and FR-33289.

Authors:  M Okuhara; Y Kuroda; T Goto; M Okamoto; H Terano; M Kohsaka; H Aoki; H Imanaka
Journal:  J Antibiot (Tokyo)       Date:  1980-01       Impact factor: 2.649

9.  Pharmacokinetics of fosmidomycin, a new phosphonic acid antibiotic.

Authors:  T Murakawa; H Sakamoto; S Fukada; T Konishi; M Nishida
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

10.  The mechanism of action of fosfomycin (phosphonomycin).

Authors:  F M Kahan; J S Kahan; P J Cassidy; H Kropp
Journal:  Ann N Y Acad Sci       Date:  1974-05-10       Impact factor: 5.691

View more
  1 in total

1.  Resistance of Francisella novicida to fosmidomycin associated with mutations in the glycerol-3-phosphate transporter.

Authors:  Ryan S Mackie; Elizabeth S McKenney; Monique L van Hoek
Journal:  Front Microbiol       Date:  2012-08-09       Impact factor: 5.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.